Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
symbols : NVS crawled date : 2021 - 12 - 20 save search
Novartis strengthens immunotherapy pipeline with option, collaboration and license agreement with BeiGene for TIGIT inhibitor ociperlimab
Published: 2021-12-20 (Crawled : 23:00) - globenewswire.com
NVS | News | $97.515 0.24% 820K
|
Health Technology
|
| O: -1.03%
H: 0.24%
C: -0.15%
BGNE | $142.065 2.21% 100K
|
Health Technology
|
| O: 8.83%
H: 0.11%
C: -4.16%
novartis license immunotherapy therapy collaboration
Sandoz submits Biologics License Application for proposed biosimilar trastuzumab to US FDA
Published: 2021-12-20 (Crawled : 23:00) - globenewswire.com
NVSEF | News | $96.0 52K
|
Health Technology
|
| O: -0.06%
H: 0.0%
C: 0.0%
NVS | News | $97.515 0.24% 820K
|
Health Technology
|
| O: 0.56%
H: 0.3%
C: 0.19%
fda application license biosimilar
BeiGene Expands Collaboration with Novartis to Develop and Commercialize BeiGene’s TIGIT Inhibitor and Market Five Novartis Oncology Medicines in China Broad Markets
Published: 2021-12-20 (Crawled : 12:30) - biospace.com/
NVS | News | $97.515 0.24% 820K
|
Health Technology
|
| O: -1.03%
H: 0.24%
C: -0.15%
BGNE | $142.065 2.21% 100K
|
Health Technology
|
| O: 8.83%
H: 0.11%
C: -4.16%
novartis china collaboration
Novartis provides an update on Phase III ligelizumab (QGE031) studies in chronic spontaneous urticaria (CSU)
Published: 2021-12-20 (Crawled : 07:00) - globenewswire.com
NVS | News | $97.515 0.24% 820K
|
Health Technology
|
| O: -1.03%
H: 0.24%
C: -0.15%
qge031 novartis urticaria
Gainers vs Losers
| 55% | 45% |
Top 10 Gainers
CSSE 4 | $0.3499 129.74% 150M
|
Consumer Services
CZOO | $11.04 121.24% 9.6M
|
BOF | $2.05 75.21% 78M
|
AMST | $3.2 60.0% 63M
|
Technology Services
LICN | $0.8592 53.43% 13M
|
WIMI | $1.05 44.75% 13M
|
Technology Services
TROO | $1.51 38.53% 5.6M
|
Manufacturing
MULN | News | $3.7 35.53% 6.4M
|
Information
RILY | $27.91 28.5% 8.9M
|
Finance
WHLM | $6.43 26.58% 580K
|
Commercial Services
Your saved searches
Save your searches and get alerts when important news are released.